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Abstract
Background: There are limited contemporary data on the presentation, management and outcomes of acute
coronary syndromes (ACS) in Sri Lanka. We aimed to identify the critical issues that limit optimal management of
ACS in Sri Lanka.
Methods: We performed a prospectively observational study of 256 consecutive patients who presented with ACS
between November 2011 and May 2012 at a tertiary care general medical unit in Sri Lanka.
Results: We evaluated data on presentation, management, in-hospital mortality, and major adverse cardiovascular
events (MACE) of participants. Smoking, alcohol abuse, and obesity were more common in patients with ST
elevation myocardial infarction (STEMI) (P < 0.05). Discharge diagnoses were STEMI in 32.8 % (84/256) and unstable
angina (UA)/non-ST elevation myocardial infarction [NSTEMI] in 67.1 % (172/256) of participants. The median time
(IQR) from onset of pain to presentation was 60 (319) minutes for STEMI and 120 (420) for UA/NSTEMI (P = 0.058). A
median delay of 240 min was noted in patients who had presented initially to smaller hospitals. Cardiac markers
were assessed in only 35 % of participants. In-hospital anti-platelet use was high (>92 %). Only 70.2 % of STEMI
patients received fibrinolytic therapy. Fewer than 20 % of patients were received fibrinolytic therapy within 30 min
of arrival. Major adverse cardiac events (MACE) were recorded in 11.9 % of subjects with STEMI and 11.6 % of those
with UA/NSTEMI (P = 0.5). According to logistic regression analysis, body mass index (P = 0.045) and duration of
diabetes (P = 0.03) were significant predictors of in-hospital MACE. On discharge, aspirin, thienopyridine, and statins
were prescribed to more than 90 % of patients. Only one patient underwent coronary angiography during the
index admission.
Conclusions: Delays in presentation and in initiation of thrombolytic therapy and coronary interventions are key
hurdles that need attention to optimize ACS care in Sri Lanka.
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Background
Sri Lanka, a developing Asian country, has a population
of 21 million and a rapidly increasing burden of non-
communicable diseases. South Asians experience higher
fatality rates and premature death attributable to cardio-
vascular disease (CVD) (deaths occurring at least 10–15
years before expected) than do persons in Western
countries [1, 2]. Cardiovascular deaths and disease
incidence have increased at an alarming rate in low and
middle-income countries [3].
In 2005, the prevalences of hypertension, diabetes, and
dysglycemia in Sri Lanka were 20, 11, and 20 %, respect-
ively [4]. Mortality from CVD in Sri Lanka is recognized
to be one of the highest causes of death worldwide [5].
Ischemic heart disease (IHD) is the leading cause of
death in Sri Lanka, accounting for 27.6 deaths per
100,000 people. Data from 2004–2012 show a steady in-
crease in mortality from IHD in hospitals; in 2012 IHD
accounted for 14.4 % of all deaths in hospitals in Sri
Lanka [6]. This high mortality rate remains unexplained,
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but may be attributable in part to a combination of
modifiable and non-modifiable cardiovascular risk fac-
tors. Previous research has shown that management of
CVD in Sri Lanka [7–9], regionally [10], and in develop-
ing countries is generally suboptimal compared to West-
ern developed countries [11].
The term acute coronary syndrome (ACS) encom-
passes a spectrum of coronary artery diseases, including
unstable angina (UA), ST-segment-elevation myocardial
infarction (STEMI), and non-ST elevation myocardial in-
farction (NSTEMI). While clinical trials have provided
clinicians with evidence for many interventions and
medications for ACS, observational studies provide use-
ful information on differences and shortcomings in man-
agement practices among countries as well as within
different regions of the same country [12, 13].
Treatment with aspirin for patients experiencing ACS
and post discharge treatment with aspirin, statins, and
blood pressure lowering drugs are cost-effective strat-
egies and considered “best practice” by the World
Health Organization [14].
Previous published studies in Sri Lanka have highlighted
the following issues in management of ACS: late presenta-
tion [8, 9], time delays between presentation and arrival to
out-patient departments and wards [9], and less than opti-
mal adherence to current ACS guidelines [7].
The aim of the current study was to gain insights into
the following aspects of ACS: epidemiology, presenta-
tion, in-ward management, and adherence to current
management guidelines, for patients admitted to a ter-
tiary care hospital in Sri Lanka.
Methods
This prospective observational study was carried out at
the Professorial Medical Unit of Teaching Hospital, Per-
adeniya, Sri Lanka over a 6-month period beginning in
November 2011. The hospital is a busy, state-run,
tertiary-care institution with nonselective intake of acute
patients.
All patients presenting to the out-patients’ department
with chest pain within the preceding 24 h and fulfilling
ECG criteria for acute STEMI, NSTEMI and UA were
included in the study. Such patients were recruited con-
secutively to avoid selection bias. A diagnosis of STEMI
was made in subjects with electrocardiographic (ECG)
changes that fulfilled current ECG criteria for the diag-
nosis of acute STEMI or new-onset left bundle-branch
block, and increased serum concentrations of biochemical
markers of myocardial necrosis where these measure-
ments were available. Diagnoses of UA and NSTEMI were
made in the presence of ischemic type chest pain and
ECG changes of ST segment depression more than 1 mm
and T wave inversion greater than 1 mm in contiguous
leads. Troponin concentrations are not checked routinely
at most government hospitals; when required, the test is
performed in a private laboratory at the patient’s expense.
The distinction between UA and NSTEMI is therefore not
routinely made because troponin concentrations are
assessed only for patients with uncertain diagnoses or for
those who are willing to pay for the test to be performed.
The initial diagnosis of ACS was made by a senior house
officer or registrar on admission and later confirmed by a
consultant physician.
Every patient presenting with chest pain underwent as-
sessment of their history, physical examination, and
ECG; those fulfilling the criteria for ACS were included
in the present study. Data on pre-hospital and in-ward
management were collected from patient records and
clarifications were made when necessary by the authors
interviewing the patients.
All participants received standard care, that is, their
participation in the study did not alter the care they re-
ceived. Ethical approval for this study was obtained from
the Ethics Review Committee of the Faculty of Medicine
of the University of Peradeniya, Sri Lanka (2011/EC/22).
Informed written consent was obtained from all partici-
pants prior to collecting data and was formally recorded.
Statistical analysis
Continuous variables are presented in means (standard
deviation) or median (inter quartile range), when skewed
in distribution. Categorical variables are presented as
proportions or percentages. ACS types were compared
via analysis for variance for continuous variables and
the χ2 test for categorical variables. A two-sided P
value <0.05 was defined as statistically significant.
Univariate and multivariate logistic regression was
used to assess possible predictors of death and in-
hospital major cardiovascular events (MACE being




The study group comprised 256 patients with confirmed
ACS, 115 (44.9 %) men and 141 (55.1 %) women. The
mean age was 63.2 (STD 11.1) years. Most patients were
in the 51–70 year age group (145, 57 %), followed by
those aged over 70 years (77, 30 %) and then by those
aged less than 50 years (34, 13.3 %). There were no sig-
nificant age variations between STEMI and UA/
NSTEMI patients. The socio-demographic profile of the
subjects is summarized in Table 1.
Discharge diagnoses were STEMI in 32.8 % (84/256)
and UA/NSTEMI in 67.1 % (172/256). The troponin
concentrations of 19 of the 84 STEMI patients were
measured and all were positive. Troponin concentrations
were measured in only 70 (40.6 %) of the remaining 172
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patients with ACS and 42 of those were positive, con-
firming a diagnosis of NSTEMI. Troponin concentra-
tions were negative in 28 of this group, so they were
categorized as having UA. Because a distinction between
UA and NSTEMI was not made in most patients in this
group, they were considered as having UA/NSTEMI.
Sixty-seven percent of patients came directly to our
center, whereas the remainder (33 %) first visited either
a general practitioner (GP) or other hospitals in which
ACS was not managed. Only 15 % of these patients were
transported to our center by ambulance, the remainder
had to provide their own transport. The median delay
during transfer was 4 h.
The median (interquartile range) delay from symptom
onset to hospital admission was shorter for STEMI pa-
tients at 60 (319) minutes than for UA/NSTEMI patients
at 120 (420) minutes (P = 0.058); this difference was not
statistically significant. For patients initially presenting to
a GP or other hospital for either STEMI or UA/
NSTEMI, there was a median delay of 240 (IQR 480)
minutes from symptom onset to hospital admission.
Baseline characteristics of the study subjects are
shown in Table 1. The body mass index (BMI) and waist
circumference of patients with STEMI were higher than
those of patients with UA/STEMI. Smoking and alcohol
abuse was more common among patients with STEMI
Table 1 Patient baseline characteristics according to discharge diagnosis and overall
Variable STEMI (n = 84) ACS (n = 172) Total (n = 256) P value
Sex Male 22 (26.2 %) 93 (54.1 %) 115 (44.9 %)
Female 62 (73.8 %) 79 (45.9 %) 141 (55.1 %)
Age (Y)-mean 62.19 (SD = 11.4) 63.7 (SD = 11.1) 63.2 (SD = 11.2) 0.316
Age Strata <50 year 13 (15.5 %) 21 (12.2 %) 34 (13.3 %) 0.564
51–70 year 49 (58.3 %) 96 (55.8 %) 145 (56.6 %)
>70 year 22 (26.2 %) 55 (31.9 %) 77 (30.1 %)
Race Sinhala 61 (72.6 %) 151 (87.8 %) 212 (82.8 %)
Muslim 15 (17.9 %) 17 (9.9 %) 32 (12.5 %)
Tamil 8 (9.5 %) 4 (2.3 %) 12 (4.7 %)
Presentation
Chest pain 75 (89.3 %) 149 (86.6 %) 224 (87.5 %) 0.546
Shortness of breath 1 (1.2 %) 6 (3.5 %) 7 (2.7 %) 0.290
Median time to present (minutes) 60 120 120 0.058
Presenting time >6 h 12 (14.3 %) 34 (19.8 %) 46 (18 %) 0.480
Delay at transfer in minutes (median) 120, IQR = 397.2 240, IQR = 720 180, IQR = 634.8 0.334
Risk Factors
Coronary artery disease/MI 7 (8.3 %) 46 (26.7 %) 53 (20.7 %) 0.001
Heart Failure 7 (8.3 %) 19 (11.2 %) 26 (10.2 %) 0.059
Stroke 0 (0 %) 7 (4.1 %) 7 (2.8 %) 0.158
Family History Of Cardio Vascular Disease 19 (22.6 %) 32 (18.9 %) 51 (20.1 %) 0.355
History of PCI or CABG 1 (1.2 %) 0 (0 %) 1 (0.4 %) 0.155
Hypertension 26 (31 %) 99 (57.6 %) 125 (48.8 %) 0.001
Dyslipidemia 7 (8.3 %) 12 (7 %) 19 (7.4 %) 0.726
Diabetes Mellitus 27 (32.1 %) 64 (37.2 %) 91 (35.5 %) 0.371
BMI mean 24.63 (SD = 5.287) 23 (SD = 3.687) 23.51 (SD = 4.312) 0.018
Normal BMI (<23 kg/m2) 34 (40.5 %) 86 (50 %) 120 (46.9 %)
Over Weight (BMI 23–27 kg/m2) 31 (36.9 %) 61 (35.5 %) 92 (35.9 %)
Obese (BMI >27 kg/m2) 19 (22.6 %) 25 (14.5 %) 44 (17.2 %)
Waist circumference (mean) in cm 85.61 83.54 84.23 0.092
Current Smoker 17 (20.2 %) 12 (7 %) 29 (11.3 %) 0.001
Alcohol Misuse 23 (27.4 %) 25 (14.5 %) 48 (18.8 %) 0.035
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than among those with UA/NSTEMI. Generally patients
with UA/NSTEMI had a worse medical history and
more risk factors than those with STEMI (Table 1).
Management in hospital and at discharge
Interventions and in-hospital treatments are shown in
Table 2. The most commonly used medications were as-
pirin (95.3 %), clopidogrel (98 %), statins (96.1 %),
angiotensin-converting enzyme (ACE)/angiotensin II re-
ceptor blockers (ARB) (87 %), and beta blockers (68.7 %)
with little differences in the medications administered
between patients with STEMI and those with UA/
NSTEMI. However, only 16 % those presenting initially
to a GP or other hospital received aspirin, compared
with 95.3 % at our center (P < 0.01). Aspirin was the
commonest medication to be withheld, either because of
presumed gastric bleeding or epigastric pain. Beta
blockers were more commonly given to patients with
STEMI (75 %) than to those with UA/NSTEMI (65.7 %,
P = 0.07) Enoxaparin or unfractionated heparin was
given to 87.8 % of patients with UA/NSTEMI and 62 %
of those with STEMI.
Fifty-nine patients (70.2 %) with STEMI underwent fi-
brinolytic therapy with streptokinase. Thirteen of the 84
Table 2 Selected in-hospital management, medications, and interventions according to discharge diagnosis
STEMI (n = 84) ACS (n = 172) Whole population (n = 256) P value
Aspirin (78) 92.9 % (166) 96.5 % (244) 95.3 % 0.194
Clopidogel (82) 97.6 % (169) 98.3 % (251) 98.0 % 0.464
Statins (81) 96.4 % (165) 95.9 % (246) 96.1 % 0.987
Beta blockers Atenolol (6) 7.1 % (23) 13.4 % (29) 11.3 % 0.073
Carvedilol (10) 11.9 % (11) 6.4 % (21) 8.2 %
Metaprolol (47) 56.0 % (79) 45.9 % (126) 49.2 %
Total (63) 75 % (113) 65.7 % (176) 68.7 %
ACEI, ARB Captopril (2) 2.4 % (21) 12.2 % (23) 9.0 % 0.946
Enalapril (66) 78.6 % (101) 58.7 % (167) 65.2 %
Losartan (5) 6 % (28) 16.3 % (33) 12.9 %
Total (73) 87 % (150) 87.2 % (223) 87.1 %
Nitrates (31) 36.9 % (72) 41.9 % (103) 40.9 % 0.145
Heparin (20) 23.8 % (28) 16.3 % (48) 18.8 % 0.167
Enoxaparin (52) 61.9 % (151) 87.8 % (203) 79.3 % 0.001
Diuretics (18) 21.4 % (25) 14.6 % (43) 16.9 % 0.209
Troponin done 19 (22.6 %) 70 (41.7 %) 89 (35.3 %) 0.004
Troponin positive in 19 (100 %) 42 (60 %) 61 (23.8 %) -
Fibrinolysis (59) 72.8 % (0) 0 % - -
Door to needle time: median (IQR) min 64 (55)
<30 min (10) 16.9 %
30–60 min (18) 30.5 %
>60 min (31) 52.5 %
Transferred to Ward 36 (43.3 %) 129 (78.2 %) 165 (67.6 %) 0.001
HDU 43 (58.1 %) 31 (19.3 %) 74 (30.3 %) 0.001
ICU 4 (4.8 %) 1 (0.6 %) 5 (2 %) 0.028
MACE 10 (11.9 %) 20 (11.6 %) 30 (11.7 %) 0.948
Echocardiography performed in 71 (84.5 %) 164 (95.3 %) 235 (91.8 %) 0.003
EF mean (%) 43.38 (SD 18.7) 52.65 (SD 13.6) 49.65 (SD 16.0) 0.001
Stress Test planned on discharge 19 (24.1 %) 44 (26.5 %) 63 (25.7 %) 0.866
Referred for PCI 1 (1.2 %) 0 (0 %) 1 (0.39 %)
Angiogram 9 (11.5 %) 11 (6.9 %) 20 (8.4 %)
CABG 0 (0 %) 1 (0.6 %) 1 (0.4 %)
Mean duration of hospital stay 5.12 (SD = 1.430) 4.33 (SD = 2.089) 4.57 (SD = 1.946) 0.001
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(15.4%) patients with STEMI were not eligible for
thrombolytic therapy because of their late presentation.
The remaining 12 patients were eligible on the basis of
arrival time; however, three of these (3.7 %) had absolute
or relative contraindications to thrombolytic therapy; the
reasons for the remaining nine (11.1 %) eligible patients
not undergoing this treatment were unknown. Median
door-to-needle time was 64 (IQR 55) minutes. Only 10
patients (16.9 %) received thrombolytic therapy within
30 min, 28 (47.4 %) within 60 min, and 39 (66 %) within
90 min. Twenty (33.9 %) received thrombolytic therapy
more than 90 min after arriving at the hospital.
Mean duration of in-hospital stay was 5.12 (1.4) days
for patients with STEMI, which was greater than the mean
of 4.3 (2.0) days for patients with UA/NSTEMI (P < 0.01).
Overall, only 32.3 % of patients were managed in an inten-
sive care or high dependency unit.
There were no reported deaths in patients with STEMI
and two in those with UA/NSTEMI. Thirty (11.7 %) pa-
tients developed MACE, which was defined as death, re-
infarction, stroke, heart failure, or cardiogenic shock oc-
curring during their hospital stays (Table 2). One patient
with STEMI had major non-fatal bleeding.
During the index admission, 84.5 % of patients with
STEMI and 95.3 % of those with UA/NSTEMI had
transthoracic echocardiography performed. The mean
ejection fraction of patients with STEMI was 43.38 %
(18.7), which was significantly lower than the mean
ejection fraction 52.6 % (13.6) for those with UA/
STEMI (P < 0.001). Coronary angiography was per-
formed on only one patient during the index admis-
sion. At discharge, coronary angiography was planned
for 20 patients (8.4 %) and cardiac stress testing for
63 (25.7 %).
At discharge, medications prescribed included aspirin
(94.8 %), clopidogrel (97.8 %), statins (96.1 %), ACEI/
ARB (82 %), and beta-blockers (72.6 %).
Predictors of in-hospital mortality and morbidity
During the index admission, MACE occurred in 30
(11.7 %) of patients. Logistic regression showed BMI
(P = 0.045) and duration of diabetes (P = 0.03) were
significant predictors of MACE. Patients presenting
with STEMI did not have a higher risk of MACE
than UA/STEMI patients. Time to presentation, pres-
ence of hypertension, diabetes, and previous cardiac
disease were not significant predictors of MACE.
Discussion
In this study, ACS was diagnosed with reasonable accur-
acy using clinical and ECG criteria. Troponin concentra-
tions were measured only in a minority of patients
because of the non-availability of this test in the state
sector and its high cost in private-sector laboratories.
Teaching Hospital, Peradeniya is one of the two largest
tertiary-care institutions in the area; many smaller hospi-
tals redirect patients with ACS to our unit. Thus, we be-
lieve that our sample can be considered representative
of patients with ACS in this region.
The management of patients presenting with ACS in
Sri Lanka has not been well documented. Previous stud-
ies have explored the time delay to initiation of
thrombolytic therapy and adherence to guidelines [7–9].
Sri Lanka still relies heavily on medical management of
ACS as opposed to primary coronary intervention. At
present, few centers have commenced treating patients
with primary percutaneous coronary intervention (PCI)
[3].
There was no significant difference in age distribution
between patients with STEMI and those with UA/
NSTEMI, the majority of patients were in the 51–70
year age range in both groups. Patients with STEMI
tended to have fewer risk factors and less frequently had
a history of previous cardiac disease; they were however,
more often smokers and had higher BMI. Hypertension
and previous cardiac disease were notably more preva-
lent in the UA/NSTEMI group. The prevalence of risk
factors among patients in Sri Lanka with ACS has not
been reported previously. The prevalences of hyperten-
sion, diabetes, and previous cardiac disease (48.8, 35.5
and 20.7 %, respectively) found in this study are compar-
able to those reported for India (48.4, 37.6 and 14.2 %,
respectively) [10]. However, the Acute Coronary Events
– a Multinational Survey of Current Management Strat-
egies (ACCESS) investigators reported a higher preva-
lence of hypertension (STEMI 78 %, NSTE-ACS 87 %)
among ACS patients in other developing countries com-
pared to Sri Lanka and India [11].
The types of ACS diagnosed in the current study were
broadly similar to those reported for other observational
studies conducted locally and globally. Rajapakse et al.
[7] reported that 33.6 % of ACS patients in Sri Lanka
had STEMI. Mohanan and colleagues reported a similar
rate of 37 % in India. The ACCESS group of investiga-
tors reported that in developing countries 46 % of ACS
patients had STEMI and 54 % NSTEMI-ACS. Our find-
ing of 32.8 % for STEMI is marginally lower than previ-
ously reported figures.
The median time delay from symptom onset to pres-
entation was shorter in patients with STEMI than in
those with UA/NSTEMI (60 min vs. 120 min, P = 0.058);
this difference was not statistically significant. Previously
reported median pre-hospital delays for Sri Lankan pa-
tients with STEMI were 130 [8] and 720 min [9]; our re-
sults show a considerable improvement over these
previous findings. The median in-hospital delay in ad-
mitting patients to an acute care unit was 5 min in the
current study compared with previously reported figures
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of 70 [8] and 20 min [9]. Pre-hospital delays were longer
for those who sought pre-hospital care than for those
who presented directly to our institution. In previous
studies, the reported average symptom onset to treat-
ment time has ranged from 1.5–6 h globally [15]. The
ACCESS study reported median delays of 4.0 and 6.0 h
for patients with STEMI and NSTEMI-ACS, respect-
ively [11]. The European Society of Cardiology has
identified that the pre-hospital period is the most
critical phase for reducing mortality and reiterated
that efforts should be made to shorten this delay [16].
The overall use of aspirin, thienopyridines, and statins
on admission, in-ward and at discharge were satisfactory
[greater than 92 % (Table 2)]. The use of these medica-
tions did not differ significantly between patients with
STEMI and those with UA/NSTEMI. Beta blockers were
underutilized at admission (30.1 %), during hospital stay
(68.7 %), and at discharge (72.6 %). The World Health
Organization considers the use of aspirin, statins, and
blood pressure-reducing agents post discharge to be a
cost-effective strategy for patients with ACS; these medi-
cations are considered best buys [14].
In the present study, 83 % of eligible patients received
thrombolytic therapy, a result consistent with the find-
ings of Rajapakse et al., who reported that thrombolytic
therapy was administered in 84.6 % of patients with
STEMI [7]. Both figures show a tremendous improve-
ment from the 17 % reported in Sri Lanka in 1999 [9].
However, in our study, a considerable proportion of pa-
tients with STEMI (30 %) received neither thrombolytic
therapy nor PCI. Reported rates of thrombolytic therapy
are 24.7 % in Kerala, India [10] and 39 % in the ACCESS
study, which was performed in developing countries be-
sides India and Sri Lanka [11]. However the overall rates
of reperfusion therapy (PCI and coronary artery bypass
graft surgery [CABG]) in both these studies were consid-
erably higher (14 and 43.8 %, respectively) than in the
present study.
Only 1 % of our study subjects underwent an interven-
tional reperfusion procedure during the index admission.
This largely reflects the current management of patients
with ACS in the state sector, which caters to over 90 %
of the population. At present, primary PCI is being in-
troduced in few state-run cardiology units in the coun-
try. This probably reflects the limited resources of a
state run, free health care system prevalent in Sri Lanka.
However, coronary angiography and primary PCI are
available in Sri Lanka in fee levying centers [3]. Rates of
coronary angiography rates in Kerala, India were 19.6
and 18.6 % for patients with STEMI and NSTEMI-ACS,
respectively, [10], 56 and 59 %, respectively, in the AC-
CESS study [11] and 62–63 and 70–80 %, respectively,
in the second Euro Heart Survey (EHS-ACS-II) [17] and
Global Registry of Acute Coronary Events (GRACE)
[18]. The rates of PCI in the ACCESS, EHS-ACS-II, and
GRACE studies for NSTEMI/ACS and STEMI were 31
and 41 %, 35 and 58 %, and 47 and 64 % respectively [8].
There is global evidence for favoring early coronary
angiography and intervention following ACS [19, 20]. A
recent meta-analysis has shown that complete revascu-
larization (as opposed to culprit-only revascularization)
during primary PCI may have beneficial outcomes at
one year [21]. This largely reflects the non-critical ath-
erosclerotic disease burden in coronary arteries, which
unfortunately is not addressed by medical revasculariza-
tion. We believe that the available evidence strongly fa-
vors an urgent transition from medical revascularization
to PCI in Sri Lanka.
Median door-to-needle time in our study was 64 min;
the mean of 96 min was attributable to late initiation of
thrombolytic therapy in some patients. The recom-
mended door to needle time of 30 min was achieved in
only 16.9 % of study subjects. A previous study reported
a median door-to-needle time of 70 min [8]. In Malaysia
the median door-to-needle time is reportedly 48–54 min
[22]. In India, the door to needle time exceeded 30 min
in only 31 % of patients with STEMI [10].
During the index admission, MACE was observed in
11.7 % of patients; this incidence did not differ signifi-
cantly between STEMI and UA/NSTEMI groups. Two
deaths occurred in the UA/NSTEMI group and none in
the STEMI group; however, the small sample size pre-
vents drawing any definite conclusions from these find-
ings. The in-hospital mortality rates for patients with
STEMI is reportedly 8.2 % in the Kerala registry in India,
7 % in the GRACE study and 4.3 % in the ACTION
study [23]. The in-hospital mortality for patients with
UA/NSTEMI in our study (1.1 %) is low compared with
reported mortality rates of 1.8 % in India [10], 3 % in the
Euro heart survey ACS II [17], and 3.9 % in the AC-
TION study [23] for patients with NSTEMI.
Because Sri Lanka does not currently have a cardiac
registry, the outcomes of ACS following the index ad-
mission are not known. This study attempts to highlight
this deficiency and express the urgent need for better
record keeping and registration of ACS patients. With
the phased-in introduction of primary PCI in selected
centers, it would be interesting to compare treatment
and outcomes of ACS a few years in the future, just as
previous studies [7–9] have paved the way for the
current comparisons.
Implications for quality improvement
Higher BMI and duration of diabetes were significant
predictors of in-hospital MACE in the current study. Al-
though we failed to demonstrate time to treatment, and
door to needle time as significant predictors of MACE,
previous studies have shown that these factors are
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significant predictors of adverse cardiac outcomes [10].
However, delayed presentation (STEMI, median 60 min
and UA/NSTEMI, median 120 min) remains a critical
factor in the deployment of effective treatment. Late
presentation resulted in 12.3 % of patients with STEMI
not receiving fibrinolytic therapy.
Transfer of patients between GPs, smaller hospitals,
and ACS treatment facilities remain a hurdle in Sri Lan-
ka’s emergency response system. The observed median
delay of 240 min is considerable and largely attributable
to most patients having to find their own transport. Edu-
cating the public on early warning symptoms, streamlin-
ing emergency services at smaller hospitals and GP
centers, and developing outreach and emergency cardiac
response teams are critical for improving cardiac ser-
vices in Sri Lanka.
The emergency care provided was minimal in smaller
hospitals and at GP practices; only 16 % of patients with
ACS receiving aspirin or a thienopyridine. Furthermore,
only 16.9 % of patients with STEMI received thrombo-
lytic therapy within the recommended 30 min of admis-
sion. Fibrinolytic therapy was not administered to 11 %
of eligible patients for unknown reasons, implying both
deficiencies in cardiac response team training and poor
record keeping.
At the time of this study, PCI was heavily underuti-
lized in the management of ACS in Sri Lanka. Over the
last 3 years, significant efforts have been taken to train
health workers and increase the use of PCI in treating
ACS. Although the use of aspirin, thienopyridines, and
statins was satisfactory, beta blocker use was suboptimal
in our study sample. Poor utilization of beta blockers
has been reported in earlier studies [7] and clearly needs
to be addressed.
Limitations
This study is the first to compare demographic charac-
teristics, presentation and management of patients with
STEMI and NSTEMI/UA at a tertiary care center in Sri
Lanka. Because of limited resources, cardiac markers
were not measured in all patients, preventing further
characterization of the NSTEMI/UA group. The rela-
tively small sample size of 256 patients and the absence
of post discharge follow up are additional limitations of
this study.
Conclusions
The use of aspirin, thienopyridines, and statins on ad-
mission, in ward, and on discharge was satisfactory. Only
72.8 % of STEMI patients received thrombolytic therapy
and there was significant delay in initiating fibrinolysis.
Emergency care at smaller hospitals was suboptimal and
transfer of patients between hospitals was unsafe. PCI
was minimally utilized at presentation and thereafter.
Instituting safe and effective patient transfer to hospitals,
improving the training of first contact doctors, and in-
creasing the use of current PCI practices are key areas
that need to be urgently addressed.
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